Page 62 - Haematologica June

M. Krevvata et al.
A
BC
D
E
F
G
Figure 1. NSG-S mice showed higher and more rapid engraftment of primary patients’ acute myeloid leukemia (AML) samples than did NSG mice. (A) Thirty-nine of the 77 AML samples screened were engrafted (hCD45+CD33+ blasts > 0.5% in mouse bone marrow) in NSG mice. All 39 AML engrafted in NSG mice also engraft- ed in NSG-S mice. Thirty-eight AML samples did not engraft in NSG, and approximately two-thirds of these engrafted in NSG-S mice. (B) Representative flow cytometry plots of human hCD45+CD33+ leukemia cells from bone marrow (BM), spleen (SPL) and peripheral blood (PB) samples from NSG and NSG-S mice. (C) Kaplan-Meier curves show the time to sacrifice mice for all 77 AML samples. (D) Leukemia burden of 9 AML engrafted in both NSG and NSG-S mice which were sacrificed at the same time was assessed by % of human hCD45+CD33+ cells in mouse BM and SPL. Each symbol represents one mouse. (E and F) Individual mouse BM and SPL leukemia burdens of the 9 AML engrafters are shown. Solid symbols represent data from NSG mice, and empty symbols represent data from NSG-S mice. (G) Elevated levels of leukemia burden (% hCD45+CD33+ cells) were seen in NSG-S mice.
964
haematologica | 2018; 103(6)